Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 50/74 ]
NASDAQ | Common Stock
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland.
The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 15, 24 | -0.43 Decreased by -183.87% | -0.54 Increased by +21.15% |
| Aug 14, 24 | -0.71 Decreased by -373.33% | -0.65 Decreased by -9.23% |
| Apr 4, 24 | -3.59 Decreased by -5.88 K% | -0.12 Decreased by -2.89 K% |
| Jan 31, 24 | -0.17 Increased by +35.19% | -0.14 Decreased by -25.00% |
| Oct 3, 23 | -0.15 Increased by +34.78% | -0.09 Decreased by -66.67% |
| Jul 6, 23 | -0.15 Decreased by -400.00% | -0.06 Decreased by -150.00% |
| May 2, 23 | -0.06 Increased by +88.00% | -0.06 |
| Mar 23, 23 | -0.27 Decreased by -350.00% | -0.06 Decreased by -350.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 15.15 M Increased by +3.24% | -4.76 M Increased by +29.19% | Decreased by -31.41% Increased by +31.41% |
| Jun 30, 24 | 15.84 M Increased by +7.94% | -6.76 M Decreased by -0.54% | Decreased by -42.65% Increased by +6.86% |
| Mar 31, 24 | 13.43 M Decreased by -25.55% | -5.50 M Increased by +45.39% | Decreased by -40.97% Increased by +26.66% |
| Dec 31, 23 | 14.70 M Decreased by -0.84% | -3.32 M Increased by +47.39% | Decreased by -22.56% Increased by +46.94% |
| Sep 30, 23 | 14.68 M Decreased by -18.62% | -6.72 M Increased by +33.30% | Decreased by -45.79% Increased by +18.03% |
| Jun 30, 23 | 14.68 M Decreased by -20.51% | -6.72 M Increased by +66.50% | Decreased by -45.79% Increased by +57.85% |
| Mar 31, 23 | 18.04 M Decreased by -7.63% | -10.08 M Decreased by -702.63% | Decreased by -55.87% Decreased by -752.38% |
| Dec 31, 22 | 14.83 M Decreased by -24.05% | -6.30 M Decreased by -477.09% | Decreased by -42.52% Decreased by -596.51% |